AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has received a "Hold" consensus recommendation from seven research firms, with an average 1-year target price of $17.25. The company recently surpassed earnings and revenue estimates, reporting $0.23 EPS and $73.47 million in revenue. Institutional investors hold approximately 36.83% of the stock, and its current market capitalization stands at $2.14 billion.

Aurinia Pharmaceuticals (NASDAQ:AUPH) experienced a 3.1% rise this week, contributing to a substantial 292% gain over the past three years for its shareholders. The company transitioned from a loss to profitability during this period, which likely fueled the strong share price increase. Over the last twelve months, Aurinia Pharmaceuticals delivered an 81% total shareholder return, indicating recent positive sentiment.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has seen its share price increase by 292% over the last three years, including a 3.1% rise this past week and a 27% gain in the last three months. This significant growth is attributed to the company transitioning from a loss to profitability. The company has also delivered an 81% total shareholder return in the last twelve months, indicating positive sentiment.

Aurinia Pharmaceuticals (NASDAQ:AUPH) saw its share price increase by 3.1% this week, contributing to a substantial 292% gain over the past three years. This strong performance is linked to the company's successful transition from a loss-making entity to profitability. The article highlights that recent positive sentiment is also reflected in an 81% total shareholder return over the last twelve months.

Aurinia Pharmaceuticals Inc. (AUPH) reached a new 52-week high of $16.49 USD, marking an 83.69% increase over the past year, driven by strong fundamentals like $265.8M revenue and an 80.2% gross profit margin. Despite varying analyst ratings on its lupus nephritis treatment, Lupkynis, the company's financial health is rated "GREAT" by InvestingPro, indicating undervaluation and predicted continued profitability. This strong performance and positive market sentiment underscore investor confidence in Aurinia's future potential.

Aurinia Pharmaceuticals Inc. (AUPH) reached a 52-week high of $16.49 USD, marking an 83.69% increase over the past year, driven by strong fundamentals like $265.8M revenue with 20.6% growth and an 80.2% gross profit margin. Despite some analyst downgrades for its lupus nephritis treatment Lupkynis, the company maintains a "GREAT" financial health rating and analysts predict continued profitability.